Grifols (NASDAQ:GRFS) Shares Gap Up – What’s Next?

Grifols, S.A. (NASDAQ:GRFS) gapped up before the market opened on Wednesday . The stock had previously closed at $8.84, but opened at $9.16. Grifols shares last traded at $9.2530, with a volume of 160,778 shares traded.

Wall Street Analyst Weigh In

GRFS has been the topic of several analyst reports. Wall Street Zen raised shares of Grifols from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. JPMorgan Chase & Co. reduced their target price on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a research report on Monday, December 8th. Zacks Research cut Grifols from a “hold” rating to a “strong sell” rating in a research note on Friday, December 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $10.00.

Grifols Stock Performance

The company has a quick ratio of 0.93, a current ratio of 2.48 and a debt-to-equity ratio of 1.20. The stock has a market capitalization of $6.28 billion, a PE ratio of 49.18, a PEG ratio of 0.32 and a beta of 0.67. The firm has a 50 day moving average price of $8.90 and a 200-day moving average price of $9.51.

Institutional Trading of Grifols

Several institutional investors and hedge funds have recently bought and sold shares of GRFS. Brandes Investment Partners LP boosted its position in Grifols by 8.9% in the 2nd quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock worth $253,441,000 after purchasing an additional 2,294,113 shares in the last quarter. Vinva Investment Management Ltd purchased a new position in shares of Grifols during the 2nd quarter valued at approximately $256,000. State of Wyoming acquired a new position in shares of Grifols in the 2nd quarter valued at $1,729,000. Norges Bank acquired a new position in shares of Grifols in the 2nd quarter valued at $17,538,000. Finally, Vestmark Advisory Solutions Inc. purchased a new stake in Grifols during the second quarter worth $414,000.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.